Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Angew Chem Int Ed Engl. 2018 Jul 26;57(31):9875-9879. doi: 10.1002/anie.201806159. Epub 2018 Jul 6.

An In Situ Depot for Continuous Evolution of Gaseous H2 Mediated by a Magnesium Passivation/Activation Cycle for Treating Osteoarthritis.

Author information

1
Department of Chemical Engineering and Institute of Biomedical Engineering, Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu, 30013, Taiwan ROC.
2
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and School of Medicine, Tzu Chi University, Hualien, 97004, Taiwan ROC.
3
Department of Orthopaedics, National Taiwan University Hospital, Hsinchu Branch, Hsinchu, 30059, Taiwan ROC.

Abstract

Inflammation is involved in many human pathologies, including osteoarthritis (OA). Hydrogen (H2 ) is known to have anti-inflammatory effects; however, the bioavailability of directly administered H2 gas is typically poor. Herein, a local delivery system that can provide a high therapeutic concentration of gaseous H2 at inflamed tissues is proposed. The delivery system comprises poly(lactic-co-glycolic acid) microparticles that contain magnesium powder (Mg@PLGA MPs). Mg@PLGA MPs that are intra-muscularly injected close to the OA knee in a mouse model can act as an in situ depot that can evolve gaseous H2 continuously, mediated by the cycle of passivation/activation of Mg in body fluids, at a concentration that exceeds its therapeutic threshold. The analytical data that are obtained in the biochemical and histological studies indicate that the proposed Mg@PLGA MPs can effectively mitigate tissue inflammation and prevent cartilage from destruction, arresting the progression of OA changes.

KEYWORDS:

hydrogen gas; magnesium; medical gas; osteoarthritis; tissue inflammation

PMID:
29923670
DOI:
10.1002/anie.201806159

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center